Having trouble accessing articles? Reset your cache.

NanoDimension backs sight-restoring therapy developer Arctos in series A

For its first life sciences company creation deal in Europe, NanoDimension launches ophthalmic play from third fund

Newly launched Arctos will use CHF8 million in series A money to conduct preclinical work on a vector-delivered technology it believes can restore eyesight in patients whose retinal cells have degenerated, rather than those whose blindness is caused by genetic disorders.

Basel-based Arctos Ltd. has the support of NanoDimension, which led the round with a CHF6 million

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers